Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine.
Dallal
A
A
Chouinard
G
G
D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects*; D001008:Anxiety Disorders / Q000139:chemically induced* / Q000188:drug therapy; D003511:Cyclohexanols / Q000008:administration & dosage / Q000009:adverse effects*; D003865:Major Depressive Disorder / Q000139:chemically induced* / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D012008:Recurrence; D013375:Substance Withdrawal Syndrome / Q000523:psychology*; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride